

Thalidomid: Mechanistische Grundlagen der teratogenen Wirkung und Rolle in der modernen Medizin

Publikationen der Arbeitsgruppe zum Thema:

Knobloch J, Jungck D, Koch A. The Molecular Mechanisms of Thalidomide Teratogenicity and Implications for Modern Medicine. *Curr Mol Med* 2017; 17: 108-117.

Knobloch J, Jungck D, Koch A. Apoptosis induction by thalidomide: critical for limb teratogenicity but therapeutic potential in idiopathic pulmonary fibrosis? *Curr Mol Pharmacol* 2011; 4: 26-61.

Knobloch J, Rütter U. Shedding light on an old mystery: thalidomide suppresses survival pathways to induce limb defects. *Cell Cycle* 2008; 7: 1121-1127.

Knobloch J, Reimann K, Klotz LO, Rütter U. Thalidomide resistance is based on the capacity of the glutathione-dependent antioxidant defense. *Mol Pharmaceut* 2008; 5: 1138-1144.

Knobloch J, Schmitz I, Götz K, Schulze-Osthoff K, Rütter U. Thalidomide induces limb anomalies by PTEN stabilization, Akt suppression, and stimulation of caspase-dependent cell death. *Mol Cell Biol* 2008; 28: 529-538.

Knobloch J, Shaughnessy JD Jr, Rütter U. Thalidomide induces limb deformities by perturbing the Bmp/Dkk1/Wnt signaling pathway. *FASEB J* 2007; 21: 1410-1421.

Kooperationen:

- L. O. Klotz, Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Canada
- U. Rütter, Institute for Animal Developmental and Molecular Biology, Heinrich-Heine University Düsseldorf
- I. Schmitz, Systems-oriented Immunology and Inflammation Research, Helmholtz Center for Infection Research, Braunschweig
- J. D. Shaughnessy Jr., Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA